These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 26854485)
21. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Carapeti M; Aguiar RC; Goldman JM; Cross NC Blood; 1998 May; 91(9):3127-33. PubMed ID: 9558366 [TBL] [Abstract][Full Text] [Related]
22. MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development. Sheikh BN; Lee SC; El-Saafin F; Vanyai HK; Hu Y; Pang SH; Grabow S; Strasser A; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T Blood; 2015 Mar; 125(12):1910-21. PubMed ID: 25605372 [TBL] [Abstract][Full Text] [Related]
23. A novel zinc finger protein Zfp277 mediates transcriptional repression of the Ink4a/arf locus through polycomb repressive complex 1. Negishi M; Saraya A; Mochizuki S; Helin K; Koseki H; Iwama A PLoS One; 2010 Aug; 5(8):e12373. PubMed ID: 20808772 [TBL] [Abstract][Full Text] [Related]
24. [FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12]. Pébusque MJ; Chaffanet M; Popovici C; Birnbaum D Bull Cancer; 2000 Dec; 87(12):887-94. PubMed ID: 11174118 [TBL] [Abstract][Full Text] [Related]
25. MOZ is essential for maintenance of hematopoietic stem cells. Katsumoto T; Aikawa Y; Iwama A; Ueda S; Ichikawa H; Ochiya T; Kitabayashi I Genes Dev; 2006 May; 20(10):1321-30. PubMed ID: 16702405 [TBL] [Abstract][Full Text] [Related]
26. Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells. Largeot A; Paggetti J; Broséus J; Aucagne R; Lagrange B; Martin RZ; Berthelet J; Quéré R; Lucchi G; Ducoroy P; Bastie JN; Delva L Biochim Biophys Acta; 2013 Dec; 1833(12):3054-3063. PubMed ID: 23994619 [TBL] [Abstract][Full Text] [Related]
27. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Ullah M; Pelletier N; Xiao L; Zhao SP; Wang K; Degerny C; Tahmasebi S; Cayrou C; Doyon Y; Goh SL; Champagne N; Côté J; Yang XJ Mol Cell Biol; 2008 Nov; 28(22):6828-43. PubMed ID: 18794358 [TBL] [Abstract][Full Text] [Related]
28. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Kitabayashi I; Aikawa Y; Yokoyama A; Hosoda F; Nagai M; Kakazu N; Abe T; Ohki M Leukemia; 2001 Jan; 15(1):89-94. PubMed ID: 11243405 [TBL] [Abstract][Full Text] [Related]
29. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence. Shin J; Yang J; Lee JC; Baek KH Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963 [TBL] [Abstract][Full Text] [Related]
30. MOZ and BMI1 act synergistically to maintain hematopoietic stem cells. Sheikh BN; Metcalf D; Voss AK; Thomas T Exp Hematol; 2017 Mar; 47():83-97.e8. PubMed ID: 27773671 [TBL] [Abstract][Full Text] [Related]
31. A further case of acute myeloid leukaemia with inv(8)(p11q13) and MOZ-TIF2 fusion. Billio A; Steer EJ; Pianezze G; Svaldi M; Casin M; Amato B; Coser P; Cross NC Haematologica; 2002 May; 87(5):ECR15. PubMed ID: 12010678 [No Abstract] [Full Text] [Related]
32. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Smith KS; Chanda SK; Lingbeek M; Ross DT; Botstein D; van Lohuizen M; Cleary ML Mol Cell; 2003 Aug; 12(2):393-400. PubMed ID: 14536079 [TBL] [Abstract][Full Text] [Related]
33. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Yang XJ; Ullah M Oncogene; 2007 Aug; 26(37):5408-19. PubMed ID: 17694082 [TBL] [Abstract][Full Text] [Related]
35. Dysregulated ΔNp63α inhibits expression of Ink4a/arf, blocks senescence, and promotes malignant conversion of keratinocytes. Ha L; Ponnamperuma RM; Jay S; Ricci MS; Weinberg WC PLoS One; 2011; 6(7):e21877. PubMed ID: 21789189 [TBL] [Abstract][Full Text] [Related]
36. RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Wolyniec K; Wotton S; Kilbey A; Jenkins A; Terry A; Peters G; Stocking C; Cameron E; Neil JC Oncogene; 2009 Jul; 28(27):2502-12. PubMed ID: 19448675 [TBL] [Abstract][Full Text] [Related]
37. The role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors. Su J; Wang X; Bai Y; Sun M; Yao Y; Duan Y Pharmacol Res; 2021 Dec; 174():105930. PubMed ID: 34626770 [TBL] [Abstract][Full Text] [Related]
38. Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). Carapeti M; Aguiar RC; Watmore AE; Goldman JM; Cross NC Cancer Genet Cytogenet; 1999 Aug; 113(1):70-2. PubMed ID: 10459350 [TBL] [Abstract][Full Text] [Related]
39. RasV12-mediated down-regulation of CCAAT/enhancer binding protein beta in immortalized fibroblasts requires loss of p19Arf and facilitates bypass of oncogene-induced senescence. Sebastian T; Johnson PF Cancer Res; 2009 Mar; 69(6):2588-98. PubMed ID: 19276382 [TBL] [Abstract][Full Text] [Related]
40. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. Dietrich N; Bracken AP; Trinh E; Schjerling CK; Koseki H; Rappsilber J; Helin K; Hansen KH EMBO J; 2007 Mar; 26(6):1637-48. PubMed ID: 17332741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]